Citation Report
List of articles citing

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

DOI: 10.1038/s41551-018-0236-8
Nature Biomedical Engineering, 2018, 2, 578-588.

#	Paper	IF	Citations
583	Quantitative Imaging of Tumor-Associated Macrophages and Their Response to Therapy Using Cu-Labeled Macrin. **2018**, 12, 12015-12029		83
582	Supramolecular Assemblies for Macrophage Activation in Cancer Therapy. **2018**, 4, 713-714		
581	Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy. **2018**, 9, 2250		24
580	Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity. **2018**, 289, 125-145		18
579	Instructing macrophages to fight cancer. *Nature Biomedical Engineering*, **2018**, 2, 559-561	19	7
578	Cancer: Re-educating tumour-associated macrophages with nanoparticles. **2018**, 17, 468		20
577	Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. **2019**, 10, 3745		58
576	MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling. **2019**, 10, 2020		3
575	Single-Cell Intravital Microscopy of Trastuzumab Quantifies Heterogeneous in vivo Kinetics. **2020**, 97, 528-539		10
574	Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy. **2019**, 144, 3-15		29
573	The size and composition of polymeric nanocapsules dictate their interaction with macrophages and biodistribution in zebrafish. **2019**, 308, 98-108		19
572	Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. **2019**, 219, 119401		36
571	Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. **2019**, 45, 13-29		59
570	Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses. **2019**, 14, 4541-4558		10
569	A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy. **2019**, 31, e1903242		43
568	Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis. **2019**, 31, e1904156		76
567	Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy. **2019**, 13, 12671-12686		42

566	Autophagy inhibition induces the repolarisation of tumour-associated macrophages and enhances chemosensitivity of laryngeal cancer cells to cisplatin in mice. **2019**, 68, 1909-1920	21
565	Screening for new macrophage therapeutics. **2019**, 9, 7714-7729	13
564	An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. **2019**, 10, 5108	74
563	The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. **2019**, 10, 2388	101
562	Improving cancer immunotherapy through nanotechnology. **2019**, 19, 587-602	257
561	An overview of nanogel-based vaccines. **2019**, 18, 951-968	9
560	Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation. **2019**, 10, 1998	77
559	Template-confined growth of Ruddlesden-Popper perovskite micro-wire arrays for stable polarized photodetectors. **2019**, 11, 18272-18281	21
558	Discovery of potent ureido tetrahydrocarbazole derivatives for cancer treatments through targeting tumor-associated macrophages. **2019**, 183, 111741	5
557	Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy. **2019**, 225, 119515	68
556	Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and □Mannose as Adjuvants. **2019**, 30, 2811-2821	7
555	Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II. **2019**, 16, 4274-4281	11
554	Epigenetics-Based Tumor Cells Pyroptosis for Enhancing the Immunological Effect of Chemotherapeutic Nanocarriers. **2019**, 19, 8049-8058	58
553	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. **2019**, 7,	19
552	Host-Guest Chemistry in Supramolecular Theranostics. **2019**, 9, 3041-3074	68
551	Immunomodulatory Nanosystems. **2019**, 6, 1900101	147
550	Bioinspired nucleic acid structures for immune modulation. **2019**, 217, 119287	10
549	Nanoparticles from Cuttlefish Ink Inhibit Tumor Growth by Synergizing Immunotherapy and Photothermal Therapy. **2019**, 13, 8618-8629	81

548	Iron Nanoparticles for Low-Power Local Magnetic Hyperthermia in Combination with Immune Checkpoint Blockade for Systemic Antitumor Therapy. **2019**, 19, 4287-4296		113
547	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. **2019**, 48, 3771-3810		179
546	Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. **2019**, 459, 192-203		14
545	Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy. **2019**, 9, 2299-2314		50
544	Combining Nanomedicine and Immunotherapy. **2019**, 52, 1543-1554		183
543	A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages. **2019**, 10, 2272		71
542	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. **2019**, 145, 104258		61
541	Nanomaterial-Based Modulation of Tumor Microenvironments for Enhancing Chemo/Immunotherapy. **2019**, 21, 64		12
540	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. **2019**, 19, 811-827		15
539	Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy. **2019**, 20,		14
538	Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. **2019**, 60, 138-145		22
537	Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. *Nature Biomedical Engineering*, **2019**, 3, 306-317	19	113
536	Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages. **2019**, 36, 65		32
535	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. **2019**, 31, e1808303		135
534	From synthetic biology to human therapy: engineered mammalian cells. **2019**, 58, 108-116		25
533	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. **2019**, 8, e1801320		25
532	Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors. **2019**, 5, 100029		22
531	Hide and Seek: Nanomaterial Interactions With the Immune System. **2019**, 10, 133		63

530	Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. **2019**, 88, 1-14	14
529	Targeted Therapeutic-Immunomodulatory Nanoplatform Based on Noncrystalline Selenium. **2019**, 11, 45404-45415	7
528	The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer. **2019**, 48, 904-912	10
527	Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. **2019**, 9, 8426-8436	32
526	Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth. **2019**, 7, 326	59
525	Simultaneous delivery of DNA vaccine and hydrophobic adjuvant using reducible polyethylenimine-functionalized graphene oxide for activation of dendritic cells. **2019**, 80, 870-876	6
524	Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy. **2019**, 9, 7981-8000	71
523	Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development. **2019**, 11,	14
522	Molecular Repolarisation of Tumour-Associated Macrophages. **2018**, 24,	107
521	Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. **2019**, 370, 715-724	27
520	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. **2019**, 20, 854-870	21
519	A Supramolecular Nanocarrier for Delivery of Amiodarone Anti-Arrhythmic Therapy to the Heart. **2019**, 30, 733-740	14
518	In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. **2019**, 14, 89-97	424
517	Nanomedicine and macroscale materials in immuno-oncology. **2019**, 48, 351-381	91
516	Rational combination immunotherapeutic approaches for effective cancer treatment. **2019**, 294, 114-130	23
515	Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. **2020**, 154, 104192	19
514	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. **2020**, 220, 88-96	14
513	Progress on Modulating Tumor-Associated Macrophages with Biomaterials. **2020**, 32, e1902007	59

512	At the bench: Engineering the next generation of cancer vaccines. **2020**, 108, 1435-1453	14
511	Materials for Immunotherapy. **2020**, 32, e1901633	78
510	Nano-immunoimaging. **2020**, 5, 628-653	16
509	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. **2020**, 12, 413-436	27
508	Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy. **2020**, 27, 94-104.e5	8
507	Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles. **2020**, 232, 119699	38
506	Myeloid-driven mechanisms as barriers to antitumor CD8 T cell activity. **2020**, 118, 165-173	13
505	Biointerface engineering nanoplatforms for cancer-targeted drug delivery. **2020**, 15, 397-415	33
504	A supramolecular protein chaperone for vaccine delivery. **2020**, 10, 657-670	16
503	Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. **2020**, 165-166, 15-40	75
502	Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity. **2020**, 319, 77-86	21
501	Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses. **2019**, 9,	99
500	Recombination Monophosphoryl Lipid A-Derived Vacosome for the Development of Preventive Cancer Vaccines. **2020**, 12, 44554-44562	6
499	Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. **2020**, 32, e2004853	58
498	Autofluorescence Imaging of 3D Tumor-Macrophage Microscale Cultures Resolves Spatial and Temporal Dynamics of Macrophage Metabolism. **2020**, 80, 5408-5423	8
497	Reprogramming of profibrotic macrophages for treatment of bleomycin-induced pulmonary fibrosis. **2020**, 12, e12034	14
496	A low-intensity focused ultrasound-assisted nanocomposite for advanced triple cancer therapy: local chemotherapy, therapeutic extracellular vesicles and combined immunotherapy. **2020**, 8, 6703-6717	5
495	Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. **2020**, 32, e2002085	45

494	Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy. **2021**, 133, 231-243	27
493	Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. **2020**, 328, 805-816	14
492	Cancer Nanomedicines in an Evolving Oncology Landscape. **2020**, 41, 730-742	12
491	Co-assembled Supramolecular Nanofibers With Tunable Surface Properties for Efficient Vaccine Delivery. **2020**, 8, 500	2
490	Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer. **2020**, 10, 7510-7526	12
489	Nanoscale Metal-Organic Framework Co-delivers TLR-7 Agonists and Anti-CD47 Antibodies to Modulate Macrophages and Orchestrate Cancer Immunotherapy. **2020**, 142, 12579-12584	39
488	In vivo microscopy reveals macrophage polarization locally promotes coherent microtubule dynamics in migrating cancer cells. **2020**, 11, 3521	4
487	Nanobiohybrids: A Synergistic Integration of Bacteria and Nanomaterials in Cancer Therapy. **2020**, 1, 25-36	17
486	Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy. **2020**, 16, e2004905	6
485	Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. **2020**, 5, 270	11
484	Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. **2020**, 12,	16
483	The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. **2020**, 10, 590941	37
482	Recent Advances on Rare Earth Upconversion Nanomaterials for Combined Tumor Near-Infrared Photoimmunotherapy. **2020**, 8, 596658	3
481	Live Cell Imaging of Nanoparticle-Cell Interactions in the Mouse Lung. **2020**, 8, 588922	4
480	Immunoadjuvants for cancer immunotherapy: A review of recent developments. **2020**, 114, 16-30	29
479	The chemical biology of IL-12 production the non-canonical NFkB pathway. **2020**, 1, 166-176	3
478	Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy. **2020**, 6, 4774-4798	12
477	Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles. **2020**, 117, 19737-19745	9

476	Lipidation Approaches Potentiate Adjuvant-Pulsed Immune Surveillance: A Design Rationale for Cancer Nanovaccine. **2020**, 8, 787	5
475	Emerging Adjuvants for Cancer Immunotherapy. **2020**, 8, 601	14
474	Imidazoquinoline-Conjugated Degradable Coacervate Conjugate for Local Cancer Immunotherapy. **2020**, 6, 4993-5000	4
473	The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. **2020**, 12, 1083-1100	11
472	Application of Nanomaterials in Biomedical Imaging and Cancer Therapy. **2020**, 10,	93
471	Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting. **2020**, 21,	7
470	Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity. **2020**, 8, 1029	2
469	Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. **2020**, 9,	11
468	Immunostimulatory biomaterials to boost tumor immunogenicity. **2020**, 8, 5516-5537	2
467	Polydopamine-Mesoporous Silica Core-Shell Nanoparticles for Combined Photothermal Immunotherapy. **2020**, 12, 42499-42510	30
466	Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. **2020**, 32, e2002054	140
465	Biomedical nanomaterials for immunological applications: ongoing research and clinical trials. **2020**, 2, 5046-5089	16
464	Chemical Strategies to Boost Cancer Vaccines. **2020**, 120, 11420-11478	29
463	Tackling TAMs for Cancer Immunotherapy: It's Nano Time. **2020**, 41, 701-714	20
462	Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy. **2020**, 8, 597806	20
461	Immunostimulatory DNA Nanogel Enables Effective Lymphatic Drainage and High Vaccine Efficacy. **2020**, 2, 1606-1614	10
460	Nanoparticles for immunotherapy. **2020**, 265-306	4
459	Targeting Pro-Tumoral Macrophages in Early Primary and Metastatic Breast Tumors with the CD206-Binding mUNO Peptide. **2020**, 17, 2518-2531	11

458	Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. **2020**, 41, 970-985	19
457	PDPN is a prognostic biomarker and correlated with immune infiltrating in gastric cancer. **2020**, 99, e19957	5
456	Supramolecular Polysaccharide Nanotheranostics that Inhibit Cancer Cells Growth and Monitor Targeted Therapy Response. **2020**, 4, 156-172	4
455	Single-cell biophysical study reveals deformability and internal ordering relationship in T cells. **2020**, 16, 5669-5678	5
454	Functional Gadofullerene Nanoparticles Trigger Robust Cancer Immunotherapy Based on Rebuilding an Immunosuppressive Tumor Microenvironment. **2020**, 20, 4487-4496	26
453	Dissolved oxygen from microalgae-gel patch promotes chronic wound healing in diabetes. **2020**, 6, eaba4311	76
452	Tumor Targeting by Integrin-Specific Lipid Nanoparticles Occurs Phagocyte Hitchhiking. **2020**, 14, 7832-7846	28
451	Biomimetic Matrix Stiffness Modulates Hepatocellular Carcinoma Malignant Phenotypes and Macrophage Polarization through Multiple Modes of Mechanical Feedbacks. **2020**, 6, 3994-4004	3
450	Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1). **2020**, 12,	3
449	Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles. **2020**, 142, 12133-12139	21
448	Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. **2020**, 10, 2110-2124	44
447	Mesoporous Bi-Containing Radiosensitizer Loading with DOX to Repolarize Tumor-Associated Macrophages and Elicit Immunogenic Tumor Cell Death to Inhibit Tumor Progression. **2020**, 12, 31225-31234	13
446	An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy. **2020**, 20, 4901-4909	28
445	Differently Charged Super-Paramagnetic Iron Oxide Nanoparticles Preferentially Induced M1-Like Phenotype of Macrophages. **2020**, 8, 537	16
444	Supramolecular Self-Assembled Nanostructures for Cancer Immunotherapy. **2020**, 8, 380	13
443	Generation of Myeloid Cells in Cancer: The Spleen Matters. **2020**, 11, 1126	16
442	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. **2020**, 10, 899	20
441	Immunostimulatory TLR7 agonist-nanoparticles together with checkpoint blockade for effective cancer immunotherapy. **2020**, 3, 1900200	5

440	The expanding landscape of inflammatory cells affecting cancer therapy. *Nature Biomedical Engineering*, **2020**, 4, 489-498	19	16
439	A novel β-cyclodextrin-rhein conjugate for improving the water solubility and bioavailability of rhein. **2020**, 490, 107958		7
438	Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy. **2020**, 20, 2246-2256		41
437	Mannosylated Nanotrinity-Mediated Macrophage Remodeling Combats Infection. **2020**, 14, 3980-3990		11
436	Pharmacological targets of metabolism in disease: Opportunities from macrophages. **2020**, 210, 107521		13
435	Targeting macrophages: a novel avenue for cancer drug discovery. **2020**, 15, 561-574		21
434	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. **2020**, 10, 3099-3117		34
433	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. **2020**, 11, 223		29
432	Nanotechnologies for enhancing cancer immunotherapy. **2020**, 13, 2595-2616		14
431	M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects. **2020**, 6, 1208-1222		46
430	High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. **2020**, 6, eaba5542		25
429	Immunomodulation-Enhanced Nanozyme-Based Tumor Catalytic Therapy. **2020**, 32, e2003563		91
428	Reprogramming Tumor Associated Macrophages toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy. **2020**, 3, 1900181		13
427	Supramolecular Prodrug Nanovectors for Active Tumor Targeting and Combination Immunotherapy of Colorectal Cancer. **2020**, 7, 1903332		41
426	Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes. **2020**, 11, 372-382		11
425	Enzyme-instructed assembly of a cholesterol conjugate promotes pro-inflammatory macrophages and induces apoptosis of cancer cells. **2020**, 8, 2007-2017		6
424	Biology and therapeutic targeting of tumour-associated macrophages. **2020**, 250, 573-592		41
423	Cyclodextrins in drug delivery: applications in gene and combination therapy. **2020**, 10, 661-677		32

422	Mechanisms of Resistance to PD-1 Checkpoint Blockade. **2020**, 80, 459-465	4
421	Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. **2020**, 12, e1612	10
420	Quantum dot-pulsed dendritic cell vaccines plus macrophage polarization for amplified cancer immunotherapy. **2020**, 242, 119928	29
419	Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). **2020**, 10, 1873-1883	15
418	Development of RNA/DNA Hydrogel Targeting Toll-Like Receptor 7/8 for Sustained RNA Release and Potent Immune Activation. **2020**, 25,	12
417	Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona. **2020**, 21,	8
416	Improving nanotherapy delivery and action through image-guided systems pharmacology. **2020**, 10, 968-997	28
415	Biodegradable Polymeric Multilayer Capsules for Therapy of Lung Cancer. **2020**, 12, 5610-5623	24
414	Enhancing cancer immunotherapy with nanomedicine. **2020**, 20, 321-334	245
413	Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle. **2020**, 13, 83-94	16
412	Spider venom administration impairs glioblastoma growth and modulates immune response in a non-clinical model. **2020**, 10, 5876	8
411	Understanding the In Vivo Fate of Advanced Materials by Imaging. **2020**, 30, 1910369	4
410	Advances in engineering local drug delivery systems for cancer immunotherapy. **2020**, 12, e1632	17
409	Macrophage M1/M2 polarization. **2020**, 877, 173090	190
408	Nanoparticle Uptake in a Spontaneous and Immunocompetent Woodchuck Liver Cancer Model. **2020**, 14, 4698-4715	13
407	PAM3 protects against DSS-induced colitis by altering the M2:M1 ratio. **2020**, 10, 6078	5
406	Potential drug delivery nanosystems for improving tumor penetration. **2020**, 151, 220-238	9
405	Improving Cancer Immunotherapy Outcomes Using Biomaterials. **2020**, 132, 17484-17495	4

404	Improving Cancer Immunotherapy Outcomes Using Biomaterials. **2020**, 59, 17332-17343	21
403	Targeting tumor-associated macrophages in head and neck squamous cell carcinoma. **2020**, 106, 104723	12
402	Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers. **2020**, 200, 155-162	7
401	Highly Branched Polydimethylacrylamide Copolymers as Functional Biomaterials. **2021**, 22, 86-94	5
400	Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy. **2021**, 133, 12792-12815	9
399	Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy. **2021**, 60, 12682-12705	56
398	Nanotechnology-Based CAR-T Strategies for Improving Efficacy and Safety of Tumor Immunotherapy. **2021**, 31, 2004713	5
397	Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. **2021**, 266, 120431	42
396	Deep Tissue Translocation of Graphene Oxide Sheets in Human Glioblastoma 3D Spheroids and an Orthotopic Xenograft Model. **2021**, 4, 2000109	5
395	Beta-d-glucan-based drug delivery system and its potential application in targeting tumor associated macrophages. **2021**, 253, 117258	15
394	electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. **2021**, 266, 120432	19
393	Folic acid-modified Exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis. **2021**, 6, 963-974	26
392	Carrier-free nanodrugs for safe and effective cancer treatment. **2021**, 329, 805-832	27
391	Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy. **2021**, 268, 120552	6
390	Macrophage imaging and subset analysis using single-cell RNA sequencing. **2021**, 5, 36-56	2
389	and osteogenesis up-regulated by two-dimensional nanosheets through a macrophage-mediated pathway. **2021**, 9, 780-794	1
388	Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs. **2021**, 81, 671-684	15
387	Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. **2021**, 330, 1080-1094	13

386	Enhancing antibody-dependent cellular phagocytosis by Re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. **2021**, 268, 120601	18
385	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. **2021**, 36, 101023	16
384	Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression.. **2021**, 4, 277-294	1
383	Considerations for designing preclinical cancer immune nanomedicine studies. **2021**, 16, 6-15	25
382	Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating and Encapsulated Drug Delivery. **2021**, 4, 2000125	2
381	Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer. **2021**, 298, 123-132	8
380	A spontaneously formed and self-adjuvanted hydrogel vaccine triggers strong immune responses. **2021**, 197, 109232	10
379	Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer. **2021**, 157, 105606	3
378	Polymeric materials for immune engineering: Molecular interaction to biomaterial design. **2021**, 133, 139-152	11
377	Fighting Cancer Using Nanoparticles Diagnosis, Treatment and Monitoring. **2021**, 657-669	
376	Nanoparticle-Mediated Lipid Metabolic Reprogramming of T Cells in Tumor Microenvironments for Immunometabolic Therapy. **2021**, 13, 31	10
375	Inorganic material based macrophage regulation for cancer therapy: basic concepts and recent advances. **2021**, 9, 4568-4590	10
374	Research trends in pharmacological modulation of tumor-associated macrophages. **2021**, 11, e288	11
373	Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?. **2021**, 11, 7471-7487	5
372	Self-Activatable Photo-Extracellular Vesicle for Synergistic Trimodal Anticancer Therapy. **2021**, 33, e2005562	29
371	Polymer nanoparticles regulate macrophage repolarization for antitumor treatment. **2021**, 57, 6919-6922	4
370	Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages. **2021**, 9, 6597-6608	4
369	The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. **2021**, 11, 1568-1593	16

368	Subcellular Drug Depots as Reservoirs for Small-Molecule Drugs. **2021**, 397-434	
367	Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis. **2021**, 33, e2007557	28
366	Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. **2020**, 8, 607209	30
365	Nanoparticles breakthroughs tumor treatment limitations by regulating tumor immune microenvironment to enhance tumor immunotherapy efficacy. **2021**, 2, 314-321	
364	Curcumin Encapsulated in Crosslinked Cyclodextrin Nanoparticles Enables Immediate Inhibition of Cell Growth and Efficient Killing of Cancer Cells. **2021**, 11,	4
363	Tailoring Materials for Modulation of Macrophage Fate. **2021**, 33, e2004172	37
362	Stimulation and Suppression of the Innate Immune System through Nanotechnology. **2021**, 4, 2303-2316	1
361	Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor-Immune Interactions. **2021**, 10,	2
360	Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy. **2021**, 21, 2224-2231	32
359	Components from spider venom activate macrophages against glioblastoma cells: new potential adjuvants for anticancer immunotherapy. **2021**, 170, 51-68	4
358	Targeting tumor-associated macrophages to synergize tumor immunotherapy. **2021**, 6, 75	66
357	Targeting Innate Immunity in Cancer Therapy. **2021**, 9,	12
356	New Tools for Studying Macrophage Polarization: Application to Bacterial Infections.	3
355	Engineering Nanoscale Artificial Antigen-Presenting Cells by Metabolic Dendritic Cell Labeling to Potentiate Cancer Immunotherapy. **2021**, 21, 2094-2103	19
354	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. **2020**, 11, 629722	15
353	Nano-Oncologicals: A Tortoise Trail Reaching New Avenues. 2009860	4
352	Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer. **2021**, 12, 742	135
351	Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics. **2021**, 16, 869-880	4

350	CaCO-Encapsulated Au Nanoparticles Modulate Macrophages toward M1-like Phenotype.. **2021**, 4, 3214-3223	5
349	Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities.. **2021**, 4, 2732-2741	0
348	Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. **2021**, 12, 635173	6
347	Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). **2021**, 21, 535	4
346	Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy. **2021**, 13, 92	10
345	Delivery of cancer therapies by synthetic and bio-inspired nanovectors. **2021**, 20, 55	17
344	Targeting macrophages in cancer immunotherapy. **2021**, 6, 127	65
343	Systemic Immunotherapy with Micellar Resiquimod-Polymer Conjugates Triggers a Robust Antitumor Response in a Breast Cancer Model. **2021**, 10, e2100008	1
342	Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Hepatocellular Carcinoma. **2021**, 11, 621373	2
341	Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs. **2021**, 13,	2
340	Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. **2021**, 12, 1999	29
339	Highway to SuccessDeveloping Advanced Polymer Therapeutics. **2021**, 4, 2000285	4
338	Engineering biomaterials to prevent post-operative infection and fibrosis. **2021**, 11, 1675-1688	2
337	Leveraging microenvironmental synthetic lethalities to treat cancer. **2021**, 131,	6
336	Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies. **2021**, 8, 2004574	8
335	Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy. **2021**, 10,	9
334	Activable Multi-Modal Nanoprobes for Imaging Diagnosis and Therapy of Tumors. **2020**, 8, 572471	2
333	High-density lipoprotein modulates tumor-associated macrophage for chemoimmunotherapy of hepatocellular carcinoma. **2021**, 37, 101064	7

332	Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment. **2021**, 16, 2775-2787	10
331	Cancer immunotherapies revisited: state of the art of conventional treatments and next-generation nanomedicines. **2021**, 28, 935-946	5
330	Synergistic ferroptosis and macrophage re-polarization using engineering exosome-mimic M1 nanovesicles for cancer metastasis suppression. **2021**, 409, 128217	7
329	Applications of Macrocyclic Host Molecules in Immune Modulation and Therapeutic Delivery. **2021**, 9, 658548	4
328	Immunomodulation of Tumor Microenvironment by Arginine-Loaded Iron Oxide Nanoparticles for Gaseous Immunotherapy. **2021**, 13, 19825-19835	6
327	Innate and adaptive immune responses toward nanomedicines. **2021**, 11, 852-870	9
326	Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. **2021**, 12, 659659	4
325	Supramolecular Nanotherapeutics for Macrophage Immunotherapy.. **2021**, 4, 4653-4666	
324	Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Combined with Immunogenic Cell Death for Cancer Immunotherapy. **2021**, 21, 4231-4240	34
323	Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. **2021**, 64, 7507-7532	4
322	A polyamidoamine (PAMAM) derivative dendrimer with high loading capacity of TLR7/8 agonist for improved cancer immunotherapy. **2022**, 15, 510	1
321	Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. **2021**, 33, e2007576	6
320	Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes. **2021**, 12, 642285	19
319	Cyclic Arginine□Glycine□Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes. **2021**, 8, 2100370	1
318	Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. **2021**, 16, 830-839	15
317	Development of Toll-like Receptor Agonist-Loaded Nanoparticles as Precision Immunotherapy for Reprogramming Tumor-Associated Macrophages. **2021**, 13, 24442-24452	6
316	Low-dose X-ray enhanced tumor accumulation of theranostic nanoparticles for high-performance bimodal imaging-guided photothermal therapy. **2021**, 19, 155	2
315	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. **2021**, 33, e2008094	16

314	Lymph Node Delivery Strategy Enables the Activation of Cytotoxic T Lymphocytes and Natural Killer Cells to Augment Cancer Immunotherapy. **2021**, 13, 22213-22224	4
313	Nanotechnology synergized immunoengineering for cancer. **2021**, 163, 72-101	0
312	If small molecules immunotherapy comes, can the prime be far behind?. **2021**, 218, 113356	8
311	Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity. **2021**, 602, 120552	3
310	Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment. **2021**, 9, 689245	1
309	Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy. **2021**, 2, 666-681	6
308	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. **2021**, 26, 1482-1489	5
307	Redirecting macrophage function to sustain their "defender" antitumor activity. **2021**, 39, 734-737	2
306	The usage of composite nanomaterials in biomedical engineering applications. **2021**, 118, 2906-2922	7
305	Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. **2021**, 23, 90	3
304	Interferon-□teammate or opponent in the tumour microenvironment?. **2021**,	33
303	TLR7/8 Agonist and SHP2 Inhibitor Loaded Nanoparticle Enhances Macrophage Immunotherapy Efficacy. **2021**, 4, 2100086	2
302	CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion. **2021**, 11, 668349	17
301	Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages. **2021**, 21, 6031-6041	11
300	An NIR-Fluorophore-Based Theranostic for Selective Initiation of Tumor Pyroptosis-Induced Immunotherapy. **2021**, 17, e2102610	7
299	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. **2021**, 9, 707198	4
298	Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer. **2021**, 13,	4
297	Obstacles and opportunities in a forward vision for cancer nanomedicine. **2021**, 20, 1469-1479	35

296	Latitudinal and longitudinal regulation of tissue macrophages in inflammatory diseases. **2021**,	1
295	Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy.. **2021**, 4, 5871-5896	2
294	Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment. **2021**, 32, 1581-1592	1
293	A dual macrophage polarizer conjugate for synergistic melanoma therapy. **2021**, 335, 333-344	1
292	TGF- Signaling: From Tissue Fibrosis to Tumor Microenvironment. **2021**, 22,	21
291	Use of Nanoformulation to Target Macrophages for Disease Treatment. **2021**, 31, 2104487	5
290	Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. **2021**, 16, 5675-5692	2
289	Macrophage-targeted nanomedicine for chronic diseases immunotherapy. **2021**, 33, 597-597	7
288	Immunomodulatory Biomaterials for Tissue Repair. **2021**, 121, 11305-11335	16
287	Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy. **2021**, 11, 2317-2327	2
286	Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: A new platform for synergistic oncology therapy.. **2022**, 12, 924-938	1
285	CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies. **2021**, 9,	6
284	Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. **2021**, 175, 113803	13
283	Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. **2021**, 275, 120914	6
282	Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages. **2021**, 10,	1
281	Nanoparticles targeting tumor-associated macrophages: A novel anti-tumor therapy. 1	0
280	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. **2021**, 13,	4
279	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. **2021**, 442, 214009	6

278	Heat-Confined Tumor-Docking Reversible Thermogel Potentiates Systemic Antitumor Immune Response During Near-Infrared Photothermal Ablation in Triple-Negative Breast Cancer. **2021**, 10, e2100907	2
277	Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. **2021**, 9,	4
276	Biomimetic Nanoparticles Carrying a Repolarization Agent of Tumor-Associated Macrophages for Remodeling of the Inflammatory Microenvironment Following Photothermal Therapy. **2021**, 15, 15166-15179	13
275	Activating a collaborative innate-adaptive immune response to control metastasis. **2021**, 39, 1361-1374.e9	18
274	Nanomedicine-based strategies to target and modulate the tumor microenvironment. **2021**, 7, 847-862	2
273	Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models. **2021**, 13,	3
272	Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. **2021**, 9, 732192	1
271	Macrophages M1-Related Prognostic Signature in Hepatocellular Carcinoma. **2021**, 2021, 1-10	2
270	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. **2021**, 37, 102415	5
269	Polysaccharide-based nanomedicines for cancer immunotherapy: A review. **2021**, 6, 3358-3382	22
268	Evolution of the protein corona affects macrophage polarization. **2021**, 191, 192-200	1
267	Advance of nano anticancer therapies targeted on tumor-associated macrophages. **2021**, 446, 214126	2
266	Delivery strategies to overcome tumor immunotherapy resistance. **2022**, 529-547	
265	Challenges and opportunities of nanotechnology in cancer immunotherapy. **2022**, 197-239	1
264	Delivery strategies for reprogramming tumor-associated macrophages. **2022**, 83-115	
263	Image-guided cancer immunotherapy. **2022**, 427-467	
262	Macrophage reprogramming for therapy. **2021**, 163, 128-144	10
261	Substrate Viscoelasticity Amplifies Distinctions between Transient and Persistent LPS-Induced Signals.	

260	Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. **2021**, 13, 4705-4727	14
259	Leveraging Immunotherapy with Nanomedicine. **2020**, 3, 2000134	1
258	Targeting the Tumor-Associated Macrophages for Normalizing Cancer. **2020**, 245-274	1
257	Toll-Like Receptors Signaling in the Tumor Microenvironment. **2020**, 1223, 81-97	21
256	Toll-Like Receptors (TLRs) in the Tumor Microenvironment (TME): A Dragon-Like Weapon in a Non-fantasy Game of Thrones. **2020**, 1263, 145-173	8
255	Next Generation of Cancer Immunotherapy: Targeting the Cancer-Immunity Cycle with Nanotechnology. **2020**, 191-253	1
254	Membrane-core nanoparticles for cancer nanomedicine. **2020**, 156, 23-39	23
253	Chemo-physical Strategies to Advance the Functionality of Targeted Nanomedicine: The Next Generation. **2021**, 143, 538-559	54
252	Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. **2020**, 41, 881-894	7
251	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. **2020**, 217,	35
250	Autofluorescence imaging of 3D tumor-macrophage microscale cultures resolves spatial and temporal dynamics of macrophage metabolism.	6
249	Activating a collaborative innate-adaptive immune response to control breast and ovarian cancer metastasis.	2
248	Macrophage targeting in cancer. **2021**, 1499, 18-41	39
247	Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. **2020**, 6, eaaz8521	14
246	The effect of intranasally administered TLR3 agonist larifan on metabolic profile of microglial cells in rat with C6 glioma. **2018**, 90, 110-119	1
245	Nanotechnology-based Drug Delivery, Metabolism and Toxicity. **2019**, 20, 1167-1190	3
244	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. **2020**, 8, 351	22
243	Modulation of Macrophages M1/M2 Polarization Using Carbohydrate-Functionalized Polymeric Nanoparticles. **2020**, 13,	6

242	Tumor-Associated Macrophages: Protumoral Macrophages in Inflammatory Tumor Microenvironment. **2020**, 10, 556-565		14
241	Design of Nanostructure Materials to Modulate Immunosuppressive Tumour Microenvironments and Enhance Cancer Immunotherapy. **2021**, 143-172		
240	Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy. **2021**, 13,		5
239	Nanoparticle-Mediated Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy. **2021**,		3
238	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. **2021**, 184, 5309-5337		70
237	A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy. **2021**,		3
236	Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer. **2021**, 13,		2
235	Nanotechnology-enhanced immunotherapy for metastatic cancer. **2021**, 2, 100174		5
234	Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma. **2021**, 15353702211052036		1
233	High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma.		
232	Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy. **2021**, 13, 53504-53518		5
231	Nanotechnology-based products for cancer immunotherapy. **2021**, 1		1
230	Reprogramming of Neutrophils as Non-canonical Antigen Presenting Cells by Radiotherapy-Radiodynamic Therapy to Facilitate Immune-Mediated Tumor Regression. **2021**,		1
229	Nanogel antigen DDS toward overcoming immune resistance of cancer. **2020**, 35, 64-69		
228	The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors.		
227	Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes. **2021**, 12, 756722		3
226	Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. **2021**, 37, 109955		4
225	Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. *Nature Biomedical Engineering*, **2021**,	19	11

224	Identification, Characterization, and Targeting of a Rare and Temporal Dendritic Cell State that Facilitates Adaptive Immune Responses.	
223	Tumor associated macrophage and microbe: The potential targets of tumor vaccine delivery. **2021**, 180, 114046	1
222	Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. **2021**, 341, 272-284	2
221	Remodeling Macrophages by an Iron Nanotrap for Tumor Growth Suppression. **2021**,	2
220	Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies. **2021**,	3
219	Reprogramming Tumor-Associated Macrophages via ROS-Mediated Novel Mechanism of Ultra-Small Cu2Se Nanoparticles to Enhance Anti-Tumor Immunity. 2108971	6
218	Engineered Iron-Based nanoplatform amplifies repolarization of M2-Like Tumor-Associated Macrophages for enhanced cancer immunotherapy. **2021**, 433, 133847	2
217	Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. **2021**, 40, 102492	0
216	A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod.. **2021**, 13,	1
215	The Ratio of Cytotoxic Lymphocytes to M2-Like Macrophages is Prognostic in Immunogenic Tumors and Predicts Immunotherapy Response.	
214	Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance.. **2022**, 16, 359-371	5
213	The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy.. **2022**, 146, 112588	1
212	Irradiation conditioning of adjuvanted, autologous cancer cell membrane nanoparticle vaccines. **2022**, 433, 134437	2
211	Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.. **2021**, 13,	2
210	A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model.. **2022**, 20, 54	0
209	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets.. **2022**,	6
208	Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy.. **2022**, 17, 29-48	3
207	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma.	

206	Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy.. **2022**, 16, 418-432	5
205	Therapeutic exosomal vaccine for enhanced cancer immunotherapy by mediating tumor microenvironment.. **2022**, 25, 103639	0
204	Orchestrated Yolk-Shell Nanohybrids Regulate Macrophage Polarization and Dendritic Cell Maturation for Oncotherapy with Augmented Antitumor Immunity.. **2022**, e2108263	10
203	Injectable hydrogel platform with biodegradable Dawson-type polyoxometalate and R848 for combinational photothermal-immunotherapy of cancer.. **2022**,	0
202	Evaluation of Immune-Modulating Drugs for Use in Drug-eluting Microsphere Transarterial Embolization.. **2022**, 121466	1
201	Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.. **2022**,	3
200	Hybrid Membrane-Decorated Prussian Blue for Effective Cancer Immunotherapy via Tumor-Associated Macrophages Polarization and Hypoxia Relief.. **2022**, e2200389	8
199	Nanoparticle mediated targeting of toll-like receptors to treat colorectal cancer.. **2022**, 172, 16-16	0
198	Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy. **2022**, 43, 101400	2
197	Photodynamic therapy initiated immunotherapy of self-delivery re-educator by inducing immunogenic cell death and macrophage polarization. **2022**, 435, 134783	3
196	Leveraging Macrophages for Cancer Theranostics.. **2022**, 114136	2
195	Tumor microcalcification-mediated relay drug delivery for photodynamic immunotherapy of breast cancer.. **2021**, 140, 518-518	2
194	Tumor-Associated Macrophages: Therapeutic Targets of Cancer. **2022**, 279-315	
193	Role of macrophages in tumor development. **2022**, 113-164	
192	Introduction to Pharmacology of Macrophages with Drug Delivery Perspective. **2022**, 3-29	
191	Macrophages and their antitumor activity. **2022**, 165-183	
190	Delivery of Oligonucleotide Therapeutics for Macrophage Reprogramming in Inflammatory Diseases. **2022**, 357-378	
189	The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.. **2022**, 14,	0

188	Enhanced antitumor chemo-immunotherapy by local co-delivery of chemotherapeutics, immune checkpoint blocking antibody and IDO inhibitor using an injectable polypeptide hydrogel.	3
187	Tumor associated macrophages reprogramed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. **2022**,	2
186	Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies.. **2022**, 41, 68	6
185	Harnessing anti-tumor and tumor-tropism functions of macrophages via nanotechnology for tumor immunotherapy. 20210166	13
184	A pH-/Enzyme-Responsive Nanoparticle Selectively Targets Endosomal Toll-like Receptors to Potentiate Robust Cancer Vaccination.. **2022**,	3
183	Context-dependent functions of pattern recognition receptors in cancer.. **2022**,	1
182	Impact of Tumor Barriers on Nanoparticle Delivery to Macrophages.. **2022**,	0
181	Clinical relevance of tumour-associated macrophages.. **2022**,	15
180	Development of a Localized Drug Delivery System with a Step-by-Step Cell Internalization Capacity for Cancer Immunotherapy.. **2022**,	2
179	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.. **2022**, e2200027	3
178	MUC1 vaccines using □cyclodextrin grafted chitosan (CS-g-CD) as carrier via host-guest interaction elicit robust immune responses. **2022**,	1
177	Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.. **2022**, 13, 852147	0
176	pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.. **2022**, 119, e2122310119	1
175	The Mechanism of the Development of Macrophage Tolerance in Tumor Microenvironment.. **2022**, 172, 653	
174	Delivery of cisplatin and resiquimod in nanomicelles for the chemoimmunotherapy of ovarian cancer. **2022**, 13,	0
173	Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials.. **2022**, 24, 799-813	1
172	Thymosin □1 reverses M2 polarization of tumor-associated macrophages during efferocytosis.. **2022**,	0
171	A Hybrid Supramolecular Polymeric Nanomedicine for Cascade-Amplified Synergetic Cancer Therapy.. **2022**,	3

170	A Hybrid Supramolecular Polymeric Nanomedicine for Cascade-Amplified Synergetic Cancer Therapy.	1
169	Targeting tumor associated macrophages in hepatocellular carcinoma.. **2022**, 114990	0
168	Deciphering albumin-directed drug delivery by imaging.. **2022**, 114237	3
167	Transformable DNA octahedron for remodeling tumor immune microenvironment with alleviated toxicity. **2022**, 440, 135813	1
166	Fibroblast Activation Protein-□Responsive Peptide Assembling Prodrug Nanoparticles for Remodeling the Immunosuppressive Microenvironment and Boosting Cancer Immunotherapy.. **2021**, e2106296	0
165	Emerging Nanoparticle Strategies for Modulating Tumor-Associated Macrophage Polarization.. **2021**, 11,	1
164	Immunotherapy for cancer: effects of iron oxide nanoparticles on polarization of tumor-associated macrophages. **2021**, 16, 2633-2650	4
163	Nanomedicines for Tumor-Associated Macrophages. **2022**, 1-24	
162	Emerging immunological strategies: recent advances and future directions. **2021**, 15, 805	0
161	Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting.. **2021**, 11, 788365	6
160	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics.. **2021**, 23,	1
159	Notch1 signaling contributes to TLR4-triggered NF-□B activation in macrophages.. **2022**, 234, 153894	1
158	Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. **2022**, 65, 1011	1
157	Emerging role of RNA sensors in tumor microenvironment and immunotherapy.. **2022**, 15, 43	0
156	Advances of functional nanomaterials for magnetic resonance imaging and biomedical engineering applications.. **2022**, e1800	0
155	Bioorthogonal in situ assembly of nanomedicines as drug depots for extracellular drug delivery.. **2022**, 13, 2038	3
154	Data_Sheet_1.docx. **2020**,	
153	Data_Sheet_1.PDF. **2020**,	

152	Data_Sheet_1.doc. **2019**,	
151	Table_1.XLSX. **2019**,	
150	Table_2.XLSX. **2019**,	
149	Table_3.xlsx. **2019**,	
148	Data_Sheet_1.zip. **2020**,	
147	Image_1.JPEG. **2020**,	
146	Ratiometric afterglow luminescent nanoplatform enables reliable quantification and molecular imaging.. **2022**, 13, 2216	7
145	Isolating and Targeting a Highly Active, Stochastic Dendritic Cell Subpopulation for Improved Immune Responses.	
144	Artificial Assembled Macrophage Co-Deliver Black Phosphorus Quantum Dot and CDK4/6 Inhibitor for Colorectal Cancer Triple-Therapy.. **2022**, 14, 20628-20640	0
143	The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.. **2022**, 61,	1
142	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance.. **2022**, 347, 175-182	0
141	Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils. **2022**, 12,	0
140	Amelioration of systemic antitumor immune responses in cocktail therapy by immunomodulatory nanozymes. **2022**, 8,	3
139	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. **2022**, 10,	0
138	Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View. 2200024	1
137	Nanotechnology and Immunomodulators in Cancer. **2022**, 125-186	0
136	Bioengineered nanogels for cancer immunotherapy. **2022**, 51, 5136-5174	6
135	The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy. **2022**, 14, 1228	0

134	In Vivo Click Chemistry Enables Multiplexed Intravital Microscopy. 2200064	1
133	Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy. 2201614	1
132	Depletion of Mannose Receptor-Positive Tumor-Associated Macrophages via a Peptide-Targeted Star-Shaped Polyglutamate Inhibits Breast Cancer Progression in Mice.	0
131	Systematic co-delivery of dual agonists to enhance cancer immunotherapy.	1
130	Targeting tumor-associated macrophages for cancer treatment. **2022**, 12,	1
129	Injectable alginate hydrogels for synergistic tumor combination therapy through repolarization of tumor-associated macrophages. **2022**, 348, 239-249	1
128	Cationic poly(amino acid) surface functionalized manganese nanoparticles for nitric oxide-based immunotherapy and magnetic resonance imaging.	0
127	Roles of exosomal circRNAs in tumour immunity and cancer progression. **2022**, 13,	1
126	A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. **2022**,	6
125	Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: a key player in tumor immunotherapy. **2022**,	0
124	The role of toll-like receptors (TLRs) in pan-cancer. **2022**, 54, 1918-1937	
123	Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists. **2022**, 10, 1590	0
122	Small gene networks can delineate immune cell states and characterize immunotherapy response in melanoma.	
121	Establishment of a 10-gene prognostic model for gastric cancer based on the tumor immune microenvironment. **2022**, 654, 114794	
120	Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response.	0
119	Supramolecular engineering of cell membrane vesicles for cancer immunotherapy. **2022**,	2
118	Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics.	
117	Recent Advances and Challenges in Cancer Immunotherapy. **2022**, 14, 3972	3

116	New advances in pharmaceutical strategies for sensitizing anti-PD -1 immunotherapy and clinical research.	
115	Spatiotemporal control of engineered bacteria to express interferon-β by focused ultrasound for tumor immunotherapy. **2022**, 13,	4
114	Cancer Immunotherapy and Delivery System: An Update. **2022**, 14, 1630	2
113	Tissue-adhesive hydrogel for multimodal drug release to immune cells in skin. **2022**,	0
112	Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. **2022**, 121722	3
111	An Updated Overview of Cyclodextrin-Based Drug Delivery Systems for Cancer Therapy. **2022**, 14, 1748	3
110	Inhibition of SerpinB9 to enhance granzyme B-based tumor therapy by using a modified biomimetic nanoplatform with a cascade strategy. **2022**, 121723	0
109	In Situ Programming of Nanovaccines for Lymph Node-Targeted Delivery and Cancer Immunotherapy.	1
108	Lipid nanoparticle-mediated CRISPR/Cas9 gene editing and metabolic engineering for anticancer immunotherapy. **2022**,	1
107	Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. **2022**, 16, 13168-13182	3
106	Macrophage phenotype-switching in cancer. **2022**, 931, 175229	1
105	Advances in the biological mechanism and application of manganese-based nanoformulations for enhanced immunotherapy. **2022**, 46, 101583	0
104	Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma. **2022**, 22,	0
103	Role of lignin-based nanoparticles in anticancer drug delivery and bioimaging: An up-to-date review. **2022**, 221, 934-953	2
102	Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. **2022**, 190, 114525	1
101	Shaping of the Immune Landscape by Chemokine Receptors that Impacts the Clinical Outcome in Triple-Negative Breast Cancer. **2022**,	0
100	Nanomedicines for Tumor-Associated Macrophages. **2022**, 3133-3155	0
99	New opportunities for immunomodulation of the tumour microenvironment using chemical tools. **2022**, 51, 7944-7970	2

98	Multidimensional Imaging of Breast Cancer. a041330	0
97	Intratumoral delivery of TransCon TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction. **2022**, 22,	0
96	Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy. **2022**, 14, 1908	1
95	The soldiers needed to be awakened: Tumor-infiltrating immune cells. 13,	1
94	Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy. **2022**, 74, 1146-1175	1
93	Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity.	0
92	Sustained release of drug-loaded nanoparticles from injectable hydrogels enables long-term control of macrophage phenotype.	0
91	A Redox-responsive Prodrug Nanogel of TLR7/8 Agonist for Improved Cancer Immunotherapy.	0
90	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. **2022**, 2,	0
89	Major pathways involved in macrophage polarization in cancer. 13,	2
88	Immunotherapeutic Implications of Toll-Like Receptors Activation in Tumor Microenvironment. **2022**, 14, 2285	0
87	Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers. 10,	0
86	Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation. 2204335	1
85	Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy. **2022**, 22,	0
84	Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential. 2202717	0
83	Defect-Engineered Nanozyme for Targeted NIR-II Photothermal Immunotherapy of Cancer. 2206401	1
82	Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity.	0
81	Isolating and targeting a highly active, stochastic dendritic cell subpopulation for improved immune responses. **2022**, 41, 111563	0

80	Nanomedicine for advanced cancer immunotherapy. **2022**, 351, 1017-1037	0
79	Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer. **2022**, 310, 121125	1
78	Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy. **2022**, 191, 114585	0
77	Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression. **2022**, 551, 215960	0
76	Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy. **2022**, 47, 101651	0
75	Nanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates. **2022**, 47, 101641	0
74	Light and immunostimulant mediated in-situ re-education of tumor-associated macrophages by photosensitizer conjugated mannan nanoparticles for boosting immuno-photodynamic anti-metastasis therapy..	1
73	Redox-Triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt(IV)-Prodrug Chemoimmunotherapy Approach. 2200179	0
72	Intravital imaging to study cancer progression and metastasis.	1
71	TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress. 12,	0
70	Nanoparticle vaccines can be designed to induce pDC support of mDCs for increased antigen display.	0
69	Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy. **2023**, 353, 289-302	0
68	Nanomedicines in cancer immunotherapy: challenges and opportunities. **2023**, 231-246	0
67	A robust Au@Cu2-xS nanoreactor assembled by silk fibroin for enhanced intratumoral glucose depletion and redox dyshomeostasis. **2023**, 293, 121970	0
66	Tumor microenvironment-modulated multiple nanotherapeutic system for potent cancer immunotherapy and metastasis inhibition. **2023**, 48, 101702	0
65	Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO2 nanosheets prompt pro-inflammatory macrophage polarization. **2023**, 48, 101670	0
64	Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy. **2022**, 14, 2606	0
63	Dioscin Induces M1 Macrophage Polarization through Connexin-43 Channels in Tumor-associated-macrophages-mediated Melanoma Metastasis. **2022**, 154559	0

62	Toll-like receptor-targeted anti-tumor therapies: Advances and challenges. 13,	0
61	Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined with PD-1 Checkpoint Blockade.	0
60	An Apoptotic Body-based Vehicle□with Navigation for Photothermal-Immunotherapy by Precise Delivery and Tumor Microenvironment Regulation. 2212118	0
59	Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy. **2022**, 14, 6091	0
58	Dual Immunostimulatory Pathway Agonism through a Synthetic Nanocarrier Triggers Robust Anti-Tumor Immunity in Murine Glioblastoma. 2208782	0
57	Gold Nanorods and Polymer Micelles Mediated Dual TLR Stimulators Delivery System CPG@Au NRs/M-R848 Regulate Macrophages Reprogramming and DC Maturation for Enhanced Photothermal Immunotherapy of Melanoma. 2201087	0
56	Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy. **2022**, 140688	0
55	Self-Assembled TLR7/8 Agonist-Mannose Conjugate as An Effective Vaccine Adjuvant for SARS-CoV-2 RBD Trimer. **2022**, 14, 5466	0
54	Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics.	1
53	Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy. 2206001	0
52	Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy. **2022**, 20,	1
51	Multifunctional nanoparticle for cancer therapy. **2023**, 4,	1
50	The portrayal of macrophages as tools and targets: A paradigm shift in cancer management. **2023**, 121399	0
49	Tumor Acidic Microenvironment-Responsive Promodulator Iron Oxide Nanoparticles for Photothermal-Enhanced Chemodynamic Immunotherapy of Cancer.	0
48	Sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer.	0
47	Metal□phenolic network-facilitated □oe-to-friend□conversion of Melittin for cancer immunotherapy with boosted Abscopal effect.	0
46	Nanoparticle Drug Delivery Systems and Their Applications as Targeted Therapies for Triple Negative Breast Cancer. **2023**, 101070	0
45	Human macrophage-engineered vesicles for utilization in ovarian cancer treatment. 12,	0

44	Trend in biodegradable porous nanomaterials for a nticancer drug delivery.	0
43	Second near-infrared nanomaterials for cancer photothermal immunotherapy. **2023**, 17, 100339	0
42	A composite peptide-supramolecular microneedle system for melanoma immunotherapy.	0
41	Reprogramming the tumor microenvironment with biotechnology. **2023**, 27,	0
40	Targeted modulation of immune cells and tissues using engineered biomaterials.	0
39	Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells. **2023**, 18, e0277285	0
38	Modulation of Macrophages by In Situ Ligand Bridging. 2215166	0
37	Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. **2023**, 385, 106-116	0
36	Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. **2023**,	0
35	Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy. **2023**, 116, 109569	0
34	Engineered drug delivery nanosystems for tumor microenvironment normalization therapy. **2023**, 49, 101766	0
33	Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment.	0
32	Allosteric synthetic antibody (Allo-SyAb) for improved cancer immunotherapy. **2023**, 463, 142374	0
31	Targeting intracellular and extracellular receptors with nano-to-macroscale biomaterials to activate immune cells. **2023**, 357, 52-66	0
30	Nanomaterials-involved strategies for reversing the immunosuppressive factors and improving antitumor immunotherapy. **2023**, 50, 101831	0
29	An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. **2023**, 88, 104452	0
28	Nanoscale Hafnium Metal□Organic Frameworks Enhance Radiotherapeutic Effects by Upregulation of Type I Interferon and TLR7 Expression. 2202830	0
27	Antibody□drug conjugates: in search of partners of choice. **2023**, 9, 339-354	1

26	Therapeutic targeting of tumour myeloid cells. **2023**, 23, 216-237	0
25	T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles. **2023**, 14,	0
24	Tumor-Specific Photothermal-Therapy-Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles.	0
23	Thymosin 1 in cancer therapy: Immunoregulation and potential applications. **2023**, 117, 109744	0
22	Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis. **2023**, 1-54	0
21	T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma. **2023**, 162, 93-108	0
20	A hydrogel-enabled cascade amplification of radiosensitization and immune activation for cancer radiotherapy. **2023**, 462, 142201	0
19	Why Don the Mutant Cells That Evade DNA Repair Cause Cancer More Frequently? Importance of the Innate Immune System in the Tumor Microenvironment. **2023**, 24, 5026	0
18	Spatial-Drug-Laden Protease-Activatable M1 Macrophage System Targets Lung Metastasis and Potentiates Antitumor Immunity. **2023**, 17, 5354-5372	0
17	Engineering M1-derived nanovesicles loading with docosahexaenoic acid synergizes ferroptosis and immune activation for treating hepatocellular carcinoma. **2023**, 14,	0
16	Bioorthogonal Activation of TLR7 Agonists Provokes Innate Immunity to Reinforce Aptamer-Based Checkpoint Blockade. **2023**, 17, 5808-5820	0
15	Development of stimuli responsive polymeric nanomedicines modulating tumor microenvironment for improved cancer therapy. **2023**, 3, 4-30	0
14	A Metal Phenolic Nanocoordinator Launches Radiotherapeutic Cancer Pyroptosis Through an Epigenetic Mechanism. 2213425	0
13	A biomimetic nanoplatform for precise reprogramming of tumor-associated macrophages and NIR-II mediated antitumor immune activation. **2023**,	0
12	Highly Sensitive Imaging of Tumor Metastasis Based on the Targeting and Polarization of M2-like Macrophages. **2023**, 145, 7941-7951	0
11	Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs. 14,	0
10	Bionic lipoprotein loaded with chloroquine-mediated blocking immune escape improves antitumor immunotherapy. **2023**, 240, 124342	0
9	Microneedle-assisted transdermal delivery of nanoparticles: Recent insights and prospects.	0

8	Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. 14,	0
7	Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. **2023**, 9,	0
6	Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy. **2023**, 122970	0
5	Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting. **2023**, 24, 7493	0
4	Hydroxyapatite nanoparticles promote TLR4 agonist-mediated anti-tumor immunity through synergically enhanced macrophage polarization. **2023**,	0
3	Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies. **2023**, 114840	0
2	Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross presentation. **2023**,	0
1	External cold atmospheric plasma-responsive on-site hydrogel for remodeling tumor immune microenvironment. **2023**, 122162	0